000 01749cam  2200373zi 4500
0019.897936
003CaOODSP
00520221107174719
006m     o  d f      
007cr cn|||||||||
008210325e202104##oncd    obs  f000 0 eng d
020 |a9780660381329
040 |aCaOODSP|beng|erda|cCaOODSP
043 |an-cn---
0861 |aH82-29/2-2021E-PDF
24500|aAlignment among public formularies in Canada, part 2 : |boncology medicines.
264 1|aOttawa, ON : |bPatented Medicine Prices Review Board = Conseil d'examen du prix des médicaments brevetés, |cApril 2021.
264 4|c©2021
300 |a1 online resource (iii, 31 pages) : |bcolour graphs
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
500 |aIssued also in French under title: Concordance des listes de médicaments des régimes publics au Canada, partie 2 : médicaments oncologiques.
500 |aIssued also in HTML format.
504 |aIncludes bibliographical references (pages 25-26).
650 0|aPharmaceutical services insurance|zCanada.
650 0|aCancer|xTreatment|zCanada|vStatistics.
650 0|aPharmaceutical policy|zCanada.
655 7|aStatistics|2lcgft
7101 |aCanada. |bPatented Medicine Prices Review Board, |eissuing body.
77508|tConcordance des listes de médicaments des régimes publics au Canada, partie 2 : |w(CaOODSP)9.897937
85640|qPDF|s2.01 MB|uhttps://publications.gc.ca/collections/collection_2021/cepmb-pmprb/H82-29-2-2021-eng.pdf
8564 |qHTML|sN/A|uhttps://www.canada.ca/en/patented-medicine-prices-review/services/npduis/analytical-studies/formularies-part2-oncology-medicines.html